Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
about
Defining and Measuring the Affordability of New Medicines: A Systematic Review.Applications of computer-aided approaches in the development of hepatitis C antiviral agents.Hepatitis C Point-of-Care Screening in Retail Pharmacies in the United StatesHepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Suppression of autophagy by mycophenolic acid contributes to inhibition of HCV replication in human hepatoma cells.Shortening the duration of therapy for chronic hepatitis C infection.ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA.Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.In vitro fertilization for women infected by hepatitis C virus: a matched case-control study and a systematic literature review.Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4.Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism.Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C.Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.Improvement of Hepatic and Extrahepatic Complications from Chronic Hepatitis C After Antiviral Treatment: A Retrospective Analysis of German Sickness Fund Data
P2860
Q30234551-500B4285-4BF9-4D77-BC94-9D62B91BA6E9Q30238530-75B343B8-EB0F-4ACE-BFCC-26BB88956C88Q33595820-65476E81-87EC-4484-90F0-A179A3C72CE5Q37578288-1E287B5B-F166-4BB0-9EF8-8A8FF6D03B81Q37690527-FE093C2F-8E07-4A53-BCEE-E9F71D07FC3CQ38627508-ED013A76-28AB-4180-B7DA-8055675A1F9FQ38758403-BDA92589-8505-472D-8487-BE9848690D34Q38793981-1A74F7BD-100B-4D01-9460-77573CA61736Q38943009-846BEA05-03AF-4B42-A2F7-3B91FB940819Q39247347-A2CD2079-37DF-485C-AD5E-1D248F04292FQ40065692-49613CDE-11D1-4E69-9FE3-4314E74E3968Q47100523-876540A4-49F8-4C79-A2A7-AFA7CC2AC287Q51366504-326683B0-2489-4EE4-8C71-55C14989ACFBQ53381076-6671C1C3-8373-48C6-B857-115236EC5FE7Q56890376-DAA1F15B-E74F-4985-922A-64CF349DB946
P2860
Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Price and affordability of dir ...... s C virus in the United States
@ast
Price and affordability of dir ...... s C virus in the United States
@en
Price and affordability of dir ...... s C virus in the United States
@nl
type
label
Price and affordability of dir ...... s C virus in the United States
@ast
Price and affordability of dir ...... s C virus in the United States
@en
Price and affordability of dir ...... s C virus in the United States
@nl
prefLabel
Price and affordability of dir ...... s C virus in the United States
@ast
Price and affordability of dir ...... s C virus in the United States
@en
Price and affordability of dir ...... s C virus in the United States
@nl
P2860
P3181
P1476
Price and affordability of dir ...... s C virus in the United States
@en
P2093
Camilla S Graham
P2860
P2888
P3181
P356
10.1186/S13027-016-0071-Z
P407
P577
2016-05-16T00:00:00Z
P6179
1021714117